cisatracurium besylate
cisatracurium besylate is listed in the FDA National Drug Code directory with 8 NDC codes, marketed under brand name including cisatracurium besylate. Available dosage forms: injection, powder.
Drug Details
- Generic Name
- cisatracurium besylate
- Brand Names
- cisatracurium besylate
- Application Number
- ANDA212171
- Sponsor
- Zydus Pharmaceuticals USA Inc.
- NDC Codes
- 8
- Dosage Forms
- INJECTION, POWDER
- Routes
- INTRAVENOUS
- Active Ingredients
- CISATRACURIUM BESYLATE
Indications and Usage
1 INDICATIONS AND USAGE Cisatracurium besylate injection is indicated: •as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age •to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the ICU •to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older Limitations of Use Cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. Cisatracurium besylate injection is a nondepolarizing neuromuscular blocker indicated: as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age ( 1 ) to provide skeletal muscle relaxation during surgery in adults and in pediatric patients 2 to 12 years of age as a bolus or infusion maintenance ( 1 ) for mechanical ventilation in the ICU in adults ( 1 ) Limitations of Use: Cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action ( 1 )